Vaccine one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was first noted in the trivalent Sabin polio vaccine, where the amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype 1 and 3 viruses in the vaccine. This phenomenon has also been found to be a problem with the dengue vaccines currently being researched, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, −2 and −4 serotypes.
Brian Hanley (microbiologist) Brian Hanley (microbiologist) Brian Hanley (born c. 1957) is an American microbiologist and founder of Butterfly Sciences. He is known for using an experimental gene therapy to try to improve health span, and is the first subject in the study. Hanley was 60 years old as of February 2017 and holds a PhD in Microbiology from University of California, Davis. In 2009 he founded Butterfly Sciences in Davis, California to develop a gene therapy to treat HIV AIDS using a combination of GHRH and an intracellular vaccine. He has numerous articles and blog posts, and academic publications in epidemiology, biotechnology,